Additions to Management Team to Strengthen Worldwide Sales, Marketing Efforts
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated
(Nasdaq: BSTE) today announced it has expanded its management team to
strengthen the Company's worldwide marketing and sales efforts. Robert
Anacone has joined Biosite as senior vice president of worldwide marketing and
sales and Winton Gibbons was hired as senior vice president strategic and
global product marketing, a new role created to bolster pre-commercialization
market analysis and development for potential novel Biosite products. The two
positions will report to Tom Watlington, Biosite's executive vice president
and chief operating officer.
"Biosite is focused on developing ground-breaking new medical diagnostic
products," said Kim Blickenstaff, Biosite's chairman and chief executive
officer. "Novel products such as ours require long-term, continuous market
development that commences before launch and continues with strong
commercialization. These individuals bring unique strengths that we believe
will enhance Biosite's ability to identify and build new markets."
Anacone has more than thirty years of healthcare experience in the
pharmaceutical, diagnostics and life science industries. Most recently, he was
chairman, president and chief executive officer of MediSpectra (Lexington,
Mass.), a privately held medical device company developing proprietary optical
detection technology for cancer and other human tissue abnormalities. Anacone
will stay on as chairman at MediSpectra after he joins Biosite. Throughout
his career, Anacone held senior marketing and sales positions at Perceptive
Biosystems (Boston), Serono Diagnostics (Boston), Gene-Trak Systems
(Framingham, Mass.), and Hybritech (San Diego) and held sales positions at
Ortho Diagnostics, Division of Johnson & Johnson, Abbott Laboratories,
Diagnostics Division and Squibb Pharmaceuticals. Anacone received his bachelor
of science degree in economics from the University of Hartford in Hartford,
Conn. In his new role, Anacone will coordinate and manage worldwide marketing
and sales operations for Biosite.
Gibbons previously served as a sell-side analyst and principal at William
Blair & Company, where he built the firm's biotech, pharmaceutical, life
sciences and diagnostic research franchise and expertise. He covered Biosite
as a research analyst while at Blair and therefore has considerable knowledge
of Biosite's business. Previously, Mr. Gibbons spent three years as vice
president of strategy and business development for the patient care division
of Boehringer Mannheim (now part of Roche Diagnostics) where he was charged
with strategic planning, business development and new product planning. Before
that, he was director of management services at Merck & Company, and also held
manager and consultant positions at McKinsey & Company. He received his
bachelor of science degree in chemistry from Duke University and his master's
in business administration from the University of Chicago Graduate School of
Business. He serves as an advisory board member for the Center for
Biotechnology at Northwestern University's Kellogg School of Management.
The strategic and global product marketing group Gibbons will lead is
charged with developing and preparing the market for novel medical diagnostic
tests from Biosite's Discovery program. After the products are launched, the
strategic and new product marketing group will continue to work with research
and development and corporate development to plan for product improvements and
new generations of products.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com.
Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intend"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements. Forward-looking statements in
this press release include statements regarding the impact that Messrs.
Anacone and Gibbons will have on Biosite's ability to build new markets and
Biosite's ability to develop and commercialize novel products. Risks and
uncertainties include risks associated with the product development process,
including Biosite's ability to complete satisfactory clinical trials on a
timely basis, risks associated with Biosite's ability to obtain regulatory
approvals and complete other clinical and pre-market activities needed to
launch new products as currently planned, and expenses or other logistical
risks that the Company may experience in transitioning from a distributor
sales model to a direct sales model in selected international markets.
Biosite also faces risks associated with pending litigation between the
company and Roche Diagnostics Corporation and certain of its affiliates
(collectively "Roche"), including whether Biosite will be able to successfully
assert its claims against Roche, whether Biosite will be able to successfully
defend against the claims that Roche is asserting against the Company, as well
as whether the litigation will result in a significant diversion of effort by
Biosite's management and scientific personnel and/or the expenditure of funds
that exceed the Company's current estimates. Other risks that should be
considered include risks associated with changing market conditions, sales,
profitability, and the extent to which products under development are
successfully developed and gain market acceptance, risks associated with the
introduction of competitive products from companies with greater capital and
resources, and risks and expenses associated with litigation, contract
disputes, patent conflicts, product recalls, manufacturing constraints,
backlog, delays or inefficiencies, shipment problems, seasonal customer
demand, the timing of significant orders, changes in reimbursement policies,
regulatory changes, competitive pressures on average selling prices, changes
in the mix of products sold, and the other risks detailed in the Company's
most recent Annual Report on Form 10-K, as amended, Quarterly Report on Form
10-Q, and other SEC filings. The Company disclaims, however, any intent or
obligation to update these forward-looking statements. Copies of the Company's
SEC filings are available from the Investor Relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, Vice President, Corporate &
Investor Relations of Biosite Incorporated, +1-858-805-2803,
npadilla@biosite.com
|
